Annual Total Liabilities
$127.79 M
+$67.07 M+110.44%
December 31, 2023
Summary
- As of February 7, 2025, RNA annual total liabilities is $127.79 million, with the most recent change of +$67.07 million (+110.44%) on December 31, 2023.
- During the last 3 years, RNA annual total liabilities has risen by +$100.12 million (+361.76%).
- RNA annual total liabilities is now -21.25% below its all-time high of $162.26 million, reached on December 31, 2019.
Performance
RNA Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$137.39 M
+$11.00 M+8.70%
September 1, 2024
Summary
- As of February 7, 2025, RNA quarterly total liabilities is $137.39 million, with the most recent change of +$11.00 million (+8.70%) on September 1, 2024.
- Over the past year, RNA quarterly total liabilities has increased by +$81.70 million (+146.68%).
- RNA quarterly total liabilities is now -15.33% below its all-time high of $162.26 million, reached on December 31, 2019.
Performance
RNA Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
RNA Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +110.4% | +146.7% |
| 3 y3 years | +361.8% | +342.6% |
| 5 y5 years | +183.3% | - |
RNA Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +176.9% | at high | +202.4% |
| 5 y | 5-year | -21.3% | +361.8% | -15.3% | +448.3% |
| alltime | all time | -21.3% | +361.8% | -15.3% | +448.3% |
Avidity Biosciences Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $137.39 M(+8.7%) |
| Jun 2024 | - | $126.39 M(+4.8%) |
| Mar 2024 | - | $120.58 M(-5.6%) |
| Dec 2023 | $127.79 M(+110.4%) | $127.79 M(+129.4%) |
| Sep 2023 | - | $55.70 M(+7.9%) |
| Jun 2023 | - | $51.61 M(-6.3%) |
| Mar 2023 | - | $55.06 M(-9.3%) |
| Dec 2022 | $60.73 M | $60.73 M(+13.4%) |
| Sep 2022 | - | $53.56 M(+15.3%) |
| Jun 2022 | - | $46.45 M(+2.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $45.43 M(-1.6%) |
| Dec 2021 | $46.15 M(+66.8%) | $46.15 M(+48.7%) |
| Sep 2021 | - | $31.04 M(+19.2%) |
| Jun 2021 | - | $26.04 M(-9.1%) |
| Mar 2021 | - | $28.64 M(+3.5%) |
| Dec 2020 | $27.68 M(-82.9%) | $27.68 M(+6.6%) |
| Sep 2020 | - | $25.97 M(+3.6%) |
| Jun 2020 | - | $25.06 M(-6.1%) |
| Mar 2020 | - | $26.68 M(-83.6%) |
| Dec 2019 | $162.26 M(+259.7%) | $162.26 M |
| Dec 2018 | $45.11 M | - |
FAQ
- What is Avidity Biosciences annual total liabilities?
- What is the all time high annual total liabilities for Avidity Biosciences?
- What is Avidity Biosciences annual total liabilities year-on-year change?
- What is Avidity Biosciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for Avidity Biosciences?
- What is Avidity Biosciences quarterly total liabilities year-on-year change?
What is Avidity Biosciences annual total liabilities?
The current annual total liabilities of RNA is $127.79 M
What is the all time high annual total liabilities for Avidity Biosciences?
Avidity Biosciences all-time high annual total liabilities is $162.26 M
What is Avidity Biosciences annual total liabilities year-on-year change?
Over the past year, RNA annual total liabilities has changed by +$67.07 M (+110.44%)
What is Avidity Biosciences quarterly total liabilities?
The current quarterly total liabilities of RNA is $137.39 M
What is the all time high quarterly total liabilities for Avidity Biosciences?
Avidity Biosciences all-time high quarterly total liabilities is $162.26 M
What is Avidity Biosciences quarterly total liabilities year-on-year change?
Over the past year, RNA quarterly total liabilities has changed by +$81.70 M (+146.68%)